NEW YORK (GenomeWeb News) – Agilent Technologies today announced the opening of a mass spectrometry facility focused on functional genomics, proteomics, lipidomics, and metabolomics research on the National University of Ireland's Galway campus.
The collaboration is part of Agilent's Academia Program, which is aimed at assisting universities and creating research partnerships. The new Biological Mass Spectrometry Facility will rely on Agilent's Q-TOF and QQQ platforms, which will also be used for demonstration purposes for the company's customers. For its part, NUI will provide application notes and data for applications using the Agilent mass spec platforms.
The mass spectrometers will be run by primary investigators David Finn, a pharmacology and therapeutics lecturer and co-director of NUI Galway's Centre for Pain Research; Niclas Karlsson, a bioinformatics researcher; and Brendan Harhen, a biochemistry graduate who will support the center's quantitative needs.
NUI Galway Vice President for Research Terry Smith said the move is part of the institution's recent efforts to increase its mass spectrometry capacity, particularly as it applies to life science research.